United States - English - NLM (National Library of Medicine)

otsuka america pharmaceutical, inc. - aripiprazole (unii: 82vfr53i78) (aripiprazole - unii:82vfr53i78) - aripiprazole 2 mg - abilify (aripiprazole) oral tablets, orally-disintegrating tablets, and oral solution are indicated for the treatment of: - schizophrenia - acute treatment of manic and mixed episodes associated with bipolar i disorder - adjunctive treatment of major depressive disorder - irritability associated with autistic disorder - treatment of tourette's disorder abilify injection is indicated for the treatment of: - agitation associated with schizophrenia or bipolar mania abilify is contraindicated in patients with a history of a hypersensitivity reaction to aripiprazole. reactions have ranged from pruritus/urticaria to anaphylaxis [see adverse reactions (6.2)] . pregnancy exposure registry there is a pregnancy exposure registry that monitors pregnancy outcomes in women exposed to atypical antipsychotics, including abilify, during pregnancy. healthcare providers are encouraged to register patients by contacting the national pregnancy registry for atypical antipsychotics at 1-866-961-2388 or visit http://womensmentalhea

New Zealand - English - Medsafe (Medicines Safety Authority)

pharmacy retailing (nz) ltd t/a healthcare logistics - aripiprazole 20mg;   - tablet - 20 mg - active: aripiprazole 20mg   excipient: hyprolose lactose monohydrate magnesium stearate maize starch microcrystalline cellulose - abilify is indicated of the treatment of schizophrenia including maintenance of clinical improvement during continuation therapy.

Australia - English - Department of Health (Therapeutic Goods Administration)

otsuka australia pharmaceutical pty ltd - aripiprazole, quantity: 20 mg - tablet, uncoated - excipient ingredients: hyprolose; maize starch; microcrystalline cellulose; magnesium stearate; lactose monohydrate - - abilify is indicated for the treatment of schizophrenia including maintenance of clinical improvement during continuation therapy. - acute treatment of manic or mixed episodes associated with bipolar i disorder in adults as monotherapy and in combination with lithium or valproate; - maintenance treatment of manic or mixed episodes in bipolar i disorder in adults as monotherapy.

United States - English - NLM (National Library of Medicine)

h.j. harkins company, inc. - aripiprazole (unii: 82vfr53i78) (aripiprazole - unii:82vfr53i78) - aripiprazole 5 mg - abilify is indicated for the treatment of schizophrenia. the efficacy of abilify was established in four 4-6 week trials in adults and one 6-week trial in adolescents (13 to 17 years). maintenance efficacy was demonstrated in one trial in adults and can be extrapolated to adolescents [see clinical studies (14.1)] . acute treatment of manic and mixed episodes abilify is indicated for the acute treatment of manic and mixed episodes associated with bipolar i disorder, both as monotherapy and as an adjunct to lithium or valproate. efficacy as monotherapy was established in four 3-week monotherapy trials in adults and one 4-week monotherapy trial in pediatric patients (10 to 17 years). efficacy as adjunctive therapy was established in one 6-week adjunctive trial in adults [see clinical studies (14.2)] . maintenance treatment of bipolar i disorder abilify is indicated for the maintenance treatment of bipolar i disorder, both as monotherapy and as an adjunct to either lithium or valproate. maintenance efficacy was

United States - English - NLM (National Library of Medicine)

physicians total care, inc. - aripiprazole (unii: 82vfr53i78) (aripiprazole - unii:82vfr53i78) - aripiprazole 2 mg - abilify is indicated for the treatment of schizophrenia. the efficacy of abilify was established in four 4-6 week trials in adults and one 6-week trial in adolescents (13 to 17 years). maintenance efficacy was demonstrated in one trial in adults and can be extrapolated to adolescents [see clinical studies (14.1)] . acute treatment of manic and mixed episodes abilify is indicated for the acute treatment of manic and mixed episodes associated with bipolar i disorder, both as monotherapy and as an adjunct to lithium or valproate. efficacy as monotherapy was established in four 3-week monotherapy trials in adults and one 4-week monotherapy trial in pediatric patients (10 to 17 years). efficacy as adjunctive therapy was established in one 6-week adjunctive trial in adults [see clinical studies (14.2)] . maintenance treatment of bipolar i disorder abilify is indicated for the maintenance treatment of bipolar i disorder, both as monotherapy and as an adjunct to either lithium or valproate. maintenance efficacy was

United States - English - NLM (National Library of Medicine)

tya pharmaceuticals - aripiprazole (unii: 82vfr53i78) (aripiprazole - unii:82vfr53i78) - aripiprazole 5 mg - abilify is indicated for the treatment of schizophrenia. the efficacy of abilify was established in four 4-6 week trials in adults and one 6-week trial in adolescents (13 to 17 years). maintenance efficacy was demonstrated in one trial in adults and can be extrapolated to adolescents . [see clinical studies ] (14.1) acute treatment of manic and mixed episodes abilify is indicated for the acute treatment of manic and mixed episodes associated with bipolar i disorder, both as monotherapy and as an adjunct to lithium or valproate. efficacy as monotherapy was established in four 3-week monotherapy trials in adults and one 4-week monotherapy trial in pediatric patients (10 to 17 years). efficacy as adjunctive therapy was established in one 6-week adjunctive trial in adults . [see clinical studies ] (14.2) maintenance treatment of bipolar i disorder abilify is indic

United States - English - NLM (National Library of Medicine)

pd-rx pharmaceuticals, inc. - aripiprazole (unii: 82vfr53i78) (aripiprazole - unii:82vfr53i78) - aripiprazole 10 mg - abilify oral tablets, orally-disintegrating tablets, and oral solution are indicated for the treatment of: - schizophrenia [see clinical studies (14.1)] - acute treatment of manic and mixed episodes associated with bipolar i disorder [see clinical studies (14.2)] - adjunctive treatment of major depressive disorder [see clinical studies (14.3)] - irritability associated with autistic disorder [see clinical studies (14.4)] - treatment of tourette's disorder [see clinical studies (14.5)] abilify injection is indicated for the treatment of: - agitation associated with schizophrenia or bipolar mania [see clinical studies (14.6)] abilify is contraindicated in patients with a history of a hypersensitivity reaction to aripiprazole. reactions have ranged from pruritus/urticaria to anaphylaxis [see

United States - English - NLM (National Library of Medicine)

aphena pharma solutions - tennessee, llc - aripiprazole (unii: 82vfr53i78) (aripiprazole - unii:82vfr53i78) - aripiprazole 10 mg - abilify is indicated for the treatment of schizophrenia. the efficacy of abilify was established in four 4-6 week trials in adults and one 6-week trial in adolescents (13 to 17 years). maintenance efficacy was demonstrated in one trial in adults and can be extrapolated to adolescents [see clinical studies (14.1)] . acute treatment of manic and mixed episodes abilify is indicated for the acute treatment of manic and mixed episodes associated with bipolar i disorder, both as monotherapy and as an adjunct to lithium or valproate. efficacy as monotherapy was established in four 3-week monotherapy trials in adults and one 4-week monotherapy trial in pediatric patients (10 to 17 years). efficacy as adjunctive therapy was established in one 6-week adjunctive trial in adults [see clinical studies (14.2)] . maintenance treatment of bipolar i disorder abilify is indicated for the maintenance treatment of bipolar i disorder, both as monotherapy and as an adjunct to either lithium or valproate. maintenance efficacy was d

United States - English - NLM (National Library of Medicine)

tya pharmaceuticals - aripiprazole (unii: 82vfr53i78) (aripiprazole - unii:82vfr53i78) - abilify is indicated for the treatment of schizophrenia. the efficacy of abilify was established in four 4-6 week trials in adults and one 6-week trial in adolescents (13 to 17 years). maintenance efficacy was demonstrated in one trial in adults and can be extrapolated to adolescents . [see clinical studies ] (14.1) acute treatment of manic and mixed episodes abilify is indicated for the acute treatment of manic and mixed episodes associated with bipolar i disorder, both as monotherapy and as an adjunct to lithium or valproate. efficacy as monotherapy was established in four 3-week monotherapy trials in adults and one 4-week monotherapy trial in pediatric patients (10 to 17 years). efficacy as adjunctive therapy was established in one 6-week adjunctive trial in adults . [see clinical studies ] (14.2) maintenance treatment of bipolar i disorder abilify is indic

Australia - English - Department of Health (Therapeutic Goods Administration)

otsuka australia pharmaceutical pty ltd - aripiprazole, quantity: 30 mg - tablet, uncoated - excipient ingredients: lactose monohydrate; iron oxide red; maize starch; microcrystalline cellulose; magnesium stearate; hyprolose - - abilify is indicated for the treatment of schizophrenia including maintenance of clinical improvement during continuation therapy. - acute treatment of manic or mixed episodes associated with bipolar i disorder in adults as monotherapy and in combination with lithium or valproate; - maintenance treatment of manic or mixed episodes in bipolar i disorder in adults as monotherapy.